Abstract
Checkpoint inhibitors, cancer immunotherapies, are the new forms of treatment for gray zone lymphoma, a rare subtype that combines the characteristics of both Hodgkin and non-Hodgkin disease forms. Programmed cell death protein 1/programmed cell death ligand 1 (PD-L1/PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) modulate the immune system function. Immunological checkpoints can be stimulatory or inhibitory, and tumors can use these checkpoints to protect against immune system attacks. This is a case report of a difficult diagnosis and describes the most current treatment using checkpoint inhibitors, through the review of the clinical record of a patient diagnosed with gray area lymphoma in August 2019, using a descriptive and cross-sectional analysis of the clinical history and disease evolution. The case showed that pembrolizumab therapy is an effective treatment option for patients with rare gray zone lymphoma refractory to different lines of treatment. Both the diagnosis and treatment of gray area lymphoma remain a challenge for the medical and multiprofessional teams,and collaboration between them ensured effective treatment for the patient.
Recommended Citation
Rosales, Yensy Mariana Zelaya; Mesquita, Juliene Lima; Garcia, Yhasmine Delles Oliveira; Paz, Fernando Ricardo Fernandes; Campos, Naiana Castelo Branco; Leita˜o, Joa˜o Paulo de Vasconcelos; Filho, Francisco Da´rio Rocha; Filho, Ricardo Vale Albino Oliveira; Lemes, Rome´lia Pinheiro Gonc¸alves; and Duarte, Fernando Barroso
(2023)
"Use of checkpoint inhibitors in gray zone lymphoma,"
Hematology/Oncology and Stem Cell Therapy: Vol. 16
:
Iss.
1
, Article 9.
Available at: https://doi.org/10.1016/j.hemonc.2020.06.001
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Included in
Cancer Biology Commons, Hematology Commons, Oncology Commons
